Max Masucci Analyst PerformanceManaging Director, Senior Research Analyst at Roth CapitalMax Masucci is a stock analyst at Roth Capital focused in the healthcare sector, covering 11 publicly traded companies. Over the past year, Max Masucci has issued 11 stock ratings, including strong buy and buy recommendations. While full access to Max Masucci's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Max Masucci's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings26 Last 6 YearsBuy Recommendations96.15% 25 Buy RatingsCompanies Covered11 Unique Companies Ratings Distribution26RatingsDistribution of strong buy, buy, hold, and sell ratings by Max Masucci.RatingPercentageCount Strong Buy11.5%3 ratings Buy84.6%22 ratings Hold3.8%1 ratings Sell0.0%0 ratingsOut of 26 total stock ratings issued by Max Masucci at Roth Capital, the majority (84.6%) have been Buy recommendations, followed by 11.5% Strong Buy and 3.8% Hold.Best & Worst CallsBest Call0000.0%CSTLApr 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TBIOMar 2022Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ11 companiesMax Masucci, an analyst at Roth Capital, currently covers 11 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageHealthcare10 companies90.9%Technology1 company9.1%Max Masucci of Roth Capital specializes in stock coverage within the Healthcare sector, with additional focus on Technology companies.Coverage IndustriesIndustryPercentageLIFE SCIENCES TOOLS & SERVICES3 companies27.3%HEALTHCARE PROVIDERS & SERVICES3 companies27.3%BIOTECHNOLOGY3 companies27.3%ELECTRONIC EQUIPMENT, INSTRUMENTS & COMPONENTS1 company9.1%HEALTHCARE EQUIPMENT & SUPPLIES1 company9.1% About Max MasucciMax Masucci is a Managing Director, Senior Research Analyst at Roth Capital Partners covering life science and diagnostic tools, with a focus on blood-based oncology diagnostics, MRD monitoring, specialty tools, and bioprocessing technologies. Prior to joining Roth Capital Partners, Max was a strategy consultant for 908 Devices, where he advised M&A and business development efforts that supported the company's strategic transformation. Max was previously a Managing Director and Senior Research Analyst at Cowen and Canaccord Genuity, where he covered life science and diagnostic tools. Max earned a B.S. in Business Administration/Finance (Minor in Italian) from Ithaca College, where he captained the men's basketball team, and holds certificates in Al: Implications for Business Strategy and Al in Healthcare from MIT.Follow on LinkedIn Max Masucci's Ratings History at Roth Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMASS908 Devices8/12/2026Boost Price Target$10.01$13.00Buy$0.0000.00% ROITKNOAlpha Teknova8/5/2026Initiated Coverage$5.52$7.00Buy$0.0000.00% ROITKNOAlpha Teknova8/5/2026Initiated Coverage$5.61$7.00Buy$0.0000.00% ROIMASS908 Devices7/29/2026Initiated Coverage$7.03$11.00Buy$0.0000.00% ROIMASS908 Devices7/29/2026Initiated Coverage$7.60$11.00Buy$0.0000.00% ROIBDSXBiodesix6/24/2026Initiated Coverage$18.67$32.00Buy$0.0000.00% ROICSTLCastle Biosciences6/24/2026Initiated Coverage$22.12$40.00Buy$0.0000.00% ROIXGNExagen6/24/2026Initiated Coverage$4.52$8.00Buy$0.0000.00% ROIBDSXBiodesix6/24/2026Upgrade$20.04Strong-Buy$0.0000.00% ROICSTLCastle Biosciences6/24/2026Upgrade$22.91Strong-Buy$0.0000.00% ROIXGNExagen6/24/2026Upgrade$4.64Strong-Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenCitigroupUBS GroupBarclaysRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftMizuho Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
